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Abstract: 
Introduction: Magnesium sulfate (MgSC4) is the agent most commonly used for treatment of eclampsia and 
prophylaxis of eclampsia in patients with severe pre-eclampsia.  
Aims and objectives: The basic aim of the study is to analyze the role of magnesium sulphate in eclampsia and pre-
eclampsia women in Pakistan.  
Material and methods: This descriptive study was conducted in King Edward Medical University, Lahore during 
March 2018 to November 2018. This study was done with the permission of ethical committee of hospital. The data 
was collected from 100 female patients. Data was collected through a systematically designed questionnaire. The 
survey included facility characteristics, MgSO4 availability and potential barriers to its access, availability and 
distribution of clinical protocols for MgSO4 use, MgSO4 dosing regimens for the treatment of pre‐eclampsia and 
eclampsia, institutional capacity to manage MgSO4 toxicity, and preferences for different options of simplified 
MgSO4 regimens.  
Results: The data were collected from 100 female patients. Respondents reported that 24.3% of all facilities used 
MgSO4 for treatment of mild pre‐eclampsia (35.1% in Latin America, 22.7% in Asia and 18.6% in Africa). Over 90% 
of health facilities in all three regions used MgSO4 for treatment of severe pre‐eclampsia and eclampsia. With respect 
to the diagnosis and management of MgSO4 toxicity, 27.8% of all facilities reported having the capacity to routinely 
measure serum magnesium concentration.  
Conclusion: It is concluded that here was no association between adverse outcomes and maternal serum magnesium 
concentrations and no maternal mortality occurred.  Magnesium sulphate was effective in preventing recurrence of 
eclamptic fits and safe for both mother and fetus. 
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INTRODUCTION: 
Magnesium sulfate (MgSC4) is the agent most 
commonly used for treatment of eclampsia and 
prophylaxis of eclampsia in patients with severe pre-
eclampsia. It is usually given by either the 
intramuscular or intravenous routes. The 
intramuscular regimen is most commonly a 4g 
intravenous loading dose, immediately followed by 
10g intramuscularly and then by 5g intramuscularly 
every 4 hours in alternating buttocks [1]. 
agnesium sulfate (MgSO4) has been used throughout 
the 20th century for prevention of eclamptic seizures, 
and it continues to be used extensively. Empirical 
evidence supports the effectiveness of MgSO4 in 
preventing and treating eclamptic seizures, in addition 
to recent controlled clinical trials. For eclamptic 
seizure prophylaxis in preeclamptic women, MgSO4 
is superior to phenytoin, nimodipine, diazepam, and 
placebo [2]. In the multinational Collaborative 
Eclampsia Trial, MgSO4 reduced the risk of recurrent 
seizures in eclamptic women by 52% when compared 
to diazepam and by 67% when compared to phenytoin. 
The publication of these clinical trials significantly 
increased the use of MgSO4 versus other 
anticonvulsants in the United Kingdom and Ireland 
[3], where the reported use in preeclampsia increased 
from 2% to 40%.16 In addition, 60% of providers 
surveyed indicated they would use magnesium as an 
anticonvulsant for eclampsia in 1998, up from only 2% 
of eclamptic women who received MgSO4 in 1992 [4]. 
Magnesium is a unique calcium antagonist as it can act 
on most types of calcium channels in vascular smooth 
muscle and as such would be expected to decrease 
intracellular calcium [5]. 
Aims and objectives: 
The basic aim of the study is to analyze the role of 
magnesium sulphate in eclampsia and pre-eclampsia 
women in Pakistan. 
 
MATERIAL AND METHODS: 
This descriptive study was conducted in King Edward 
Medical University, Lahore during March 2018 to 
November 2018. This study was done with the 
permission of ethical committee of hospital. The data 
was collected from 100 female patients. Data was 
collected through a systematically designed 
questionnaire. The survey included facility 
characteristics, MgSO4 availability and potential 
barriers to its access, availability and distribution of 
clinical protocols for MgSO4 use, MgSO4 dosing 
regimens for the treatment of pre‐eclampsia and 
eclampsia, institutional capacity to manage 
MgSO4 toxicity, and preferences for different options 
of simplified MgSO4 regimens.  
 
Statistical analysis: 
Data analyses were mainly descriptive. Cross‐
tabulation was used to describe health facility 
characteristics, availability and use of MgSO4 by 
geographical regions.  
 
RESULTS: 
The data were collected from 100 female patients. 
Respondents reported that 24.3% of all facilities used 
MgSO4 for treatment of mild pre‐eclampsia (35.1% in 
Latin America, 22.7% in Asia and 18.6% in Africa). 
Over 90% of health facilities in all three regions used 
MgSO4 for treatment of severe pre‐eclampsia and 
eclampsia. With respect to the diagnosis and 
management of MgSO4 toxicity, 27.8% of all facilities 
reported having the capacity to routinely measure 
serum magnesium concentration. In more than half of 
all facilities, MgSO4 was administered as a loading 
dose followed by continuous intravenous maintenance 
dose, and in one‐quarter of facilities the loading dose 
was followed by intramuscular maintenance dose.  
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Figure 01: Magnesium is a potent vasodilator of uterine and mesenteric arteries, and aorta, but has minimal effect on 
cerebral arteries. In vascular smooth muscle, magnesium competes with calcium for binding sites, in this case for 
voltage-operated calcium channels (VOCC). 
Table 01: Analysis of level of MgSO4 in normal, pre-eclampsia and eclampsia patients 
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DISCUSSION: 
Magnesium sulphate therapy in pre-eclampsia has not 
been associated with improved neonatal outcome in 
the short-term. There are many confounding factors 
that contribute to adverse neonatal outcome, and 
therefore make the evaluation of the neonatal outcome 
after magnesium sulphate therapy difficult, such as 
primigravidity (52%), preterm delivery in 56 and 53% 
of preeclamptic and eclamptic women, respectively, 
and intrauterine growth restriction among 30.2% of the 
women in the present study [6]. In the Magpie study, 
more than 53% of the babies were born underweight 
(less than 2.5 kg). One should, however, take into 
account that most cases of perinatal morbidity in pre-
eclampsia usually occur very remote in time from the 
exposure to MgSO [7]. Riaz et al. evaluated the effects 
of maternal magnesium sulphate treatment on 
newborn infants delivered at 6 weeks of gestation 
whose mothers received a minimum of 12 h of 
intravenous MgSO4 , and beyond the immediate 
postdelivery period, there were no additional 
complications in this cohort attributable to prenatal 
MgSO4 exposure [8]. This has recently been 
confirmed by the follow-up of 4,483 children of the 
Magpie Trial at 18 months after exposure of their 
mothers to MgSO9 [9] . There was no increased risk of 
death or disability. Like the present study, two studies 
at the Rotunda Hospital in Dublin and the Yorkshire 
region of the UK involving 16 maternity units using a 
common guideline of MgSO4 therapy for pre-
eclampsia for a 5-year prospective study confirmed the 
outcome [10]. 
 
CONCLUSION: 
It is concluded that here was no association between 
adverse outcomes and maternal serum magnesium 
concentrations and no maternal mortality 
occurred.  Magnesium sulphate was effective in 
preventing recurrence of eclamptic fits and safe for 
both mother and fetus. 
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